EPGNF (Epigenomics AG) Receivables Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EPGNF Epigenomics AG EPGNF
18 GF Score
Price $1.12
GF Value $0.11
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Epigenomics AG's Revenue for the six months ended in Jun. 2026 was $0.02 Mil. Epigenomics AG's average Accounts Receivable for the six months ended in Jun. 2026 was $0.00 Mil.

Epigenomics AG  (OTCPK:EPGNF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Epigenomics AG Receivables Turnover Related Terms

Epigenomics AG Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Epigenomics AG's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG Receivables Turnover Chart

Epigenomics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.59 5.94 1.75 - -

Epigenomics AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Jun24 Dec24 Jun25 Dec25 Jun26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EPGNF vs TMO, DHR, NTRA: Receivables Turnover Comparison

For the Diagnostics & Research subindustry, Epigenomics AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Epigenomics AG Receivables Turnover vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Receivables Turnover falls into.


EPGNF
18GF Score
Epigenomics AG EPGNF
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epigenomics AG Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Epigenomics AG's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=0.027085870814182 / (( + ) / 1 )
=0.027085870814182 / 0
=N/A

Epigenomics AG's Receivables Turnover for the quarter that ended in Jun. 2026 is calculated as

Receivables Turnover (Q: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2026 ) / ((Accounts Receivable (Q: Dec. 2025 ) + Accounts Receivable (Q: Jun. 2026 )) / count )
=0.019830378765897 / (( + ) / 1 )
=0.019830378765897 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Epigenomics AG (EPGNF) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of $1.12 is trading 918.2% above its estimated GF Value™ of $0.11.

Key valuation signals for EPGNF:

  • Receivables Turnover:
  • GF Value™: $0.11 vs. price of $1.12 (918.2% above fair value)
  • GF Score™: 18/100 with 3 warning signs

No single metric tells the full story. See the EPGNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
18GF Score

Get the complete analysis for EPGNF

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price
$0.11
GF Value